Teleflex Incorporated Forecasted to Post FY2017 Earnings of $8.26 Per Share (NYSE:TFX)
Teleflex Incorporated (NYSE:TFX) – Analysts at William Blair boosted their FY2017 EPS estimates for shares of Teleflex in a research note issued on Thursday. William Blair analyst B. Weinstein now expects that the medical technology company will post earnings per share of $8.26 for the year, up from their previous estimate of $8.12. William Blair also issued estimates for Teleflex’s FY2018 earnings at $9.55 EPS.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $1.89 earnings per share.
TFX has been the topic of several other research reports. Barclays PLC reiterated a “buy” rating on shares of Teleflex in a research note on Monday, June 26th. Needham & Company LLC reiterated a “buy” rating on shares of Teleflex in a research note on Friday. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $228.00 price target on the stock in a research note on Friday, June 23rd. Deutsche Bank AG boosted their price target on Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a research note on Monday, May 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $230.00 price target on shares of Teleflex in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $221.17.
Teleflex (NYSE TFX) opened at 214.26 on Monday. The stock has a market capitalization of $9.64 billion, a PE ratio of 44.47 and a beta of 1.05. Teleflex has a 12 month low of $136.53 and a 12 month high of $217.97. The firm has a 50-day moving average price of $207.61 and a 200 day moving average price of $195.00.
Hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its stake in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock worth $11,692,000 after buying an additional 39,419 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Teleflex by 4.8% in the fourth quarter. Teachers Advisors LLC now owns 45,560 shares of the medical technology company’s stock worth $7,342,000 after buying an additional 2,074 shares in the last quarter. Creative Planning increased its position in shares of Teleflex by 3.7% in the first quarter. Creative Planning now owns 2,259 shares of the medical technology company’s stock worth $438,000 after buying an additional 81 shares in the last quarter. Pennsylvania Trust Co increased its position in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock worth $419,000 after buying an additional 15 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Teleflex during the first quarter worth about $349,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.
In other news, VP John Deren sold 2,246 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $194.07, for a total value of $435,881.22. Following the sale, the vice president now owns 3,989 shares in the company, valued at $774,145.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $208.41, for a total value of $41,682.00. Following the completion of the sale, the director now owns 8,080 shares in the company, valued at approximately $1,683,952.80. The disclosure for this sale can be found here. Insiders sold 10,546 shares of company stock worth $2,079,856 in the last 90 days. Company insiders own 2.39% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be paid a $0.34 dividend. The ex-dividend date is Friday, August 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.63%. Teleflex’s payout ratio is 26.00%.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.